Inicio>>Hepcidin-25 (human)

Hepcidin-25 (human)

Catalog No.GA22331

Hepcidin-25 (hepatic bactericidal protein), also referred to as LEAP-1 (liver-expressed antimicrobial peptide) has been independently discovered by two groups in human blood ultrafiltrate and urine. The peptide which is predominantly expressed in the liver, belongs to a new vertebrate family of small antimicrobial peptides that contain 8 cysteine residues and show significant antibacterial and antifungal activity. Further investigations revealed that hepicidin is the principal iron-regulatory hormone in humans. Hepcidin acts by binding to the iron exporter ferroportin, inducing its internalization and degradation, thereby blocking cellular iron efflux. Nemeth et al. demonstrated that the N-terminal part of the peptide hormone is essential for its activity. Former CAS-number 342790-21-0.

Products are for research use only. Not for human use. We do not sell to patients.

Hepcidin-25 (human) Chemical Structure

Cas No.: 1356390-47-0

Tamaño Precio Disponibilidad Cantidad
0.5mg
858,00 $
Disponible
0.1mg
277,00 $
Disponible
1mg
1.360,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Hepcidin-25 (hepatic bactericidal protein), also referred to as LEAP-1 (liver-expressed antimicrobial peptide) has been independently discovered by two groups in human blood ultrafiltrate and urine. The peptide which is predominantly expressed in the l

Reseñas

Review for Hepcidin-25 (human)

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Hepcidin-25 (human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.